A new therapeutic avenue for treating insomnia (Published in Neuropharmacology)
Researchers at IIIS succeeded in identifying the first positive allosteric modulator for adenosine A2A receptors and found that it induces sleep without affecting cardiovascular function.
Insomnia is one of the major sleep problems all over the world. However, the most widely prescribed medicines for the treatment of insomnia are plagued by a wide range of adverse effects. Their discovery may unlock the development of the next-generation sleeping pill.
The article, “Enhancing endogenous adenosine A2A receptor signaling induces slow-wave sleep without affecting body temperature and cardiovascular function” was published online in Neuropharmacology on October 15, 2018.